Puerto Rican plant to boost US supplies of heparin
This article was originally published in Scrip
Executive Summary
US FDAapproval for APP Pharmaceuticals's Puerto Rican plant to manufacture three heparin products should help ensure the uninterrupted and safe supply of heparin to the US, says the company. APP is currently the sole supplier of therapeutic heparin vials to the US after contamination problems occurred there earlier this year, says the company's CEO, Tom Silberg. Nine products are currently manufactured at the company's Puerto Rican plant, including doxycycline, azithromycin and diphenhydramine.
You may also be interested in...
Brazil Authorizes Oxford/AZ and Sinovac Vaccines
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
Success For Dutch Parallel Registration and Reimbursement Pilot
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
Constitutional Complaints In Germany Cast Doubt Over Fate Of UPC
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.
Need a specific report? 1000+ reports available
Buy Reports